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Abstract 
Extemporaneous compounding takes place in community and hospital pharmacies. There are usually specialist compounding 
pharmacies in major towns and cities, but any pharmacy may undertake compounding as long as they have appropriate facilities 
according to state-based legislation (e.g. allocated clean bench, specific compounding equipment). Although development is a 
continuous process, companies are customizing features to meet the majority of patient needs, but the very nature of the process 
cannot meet all patient needs. The risk-benefit ratio of using traditionally compounded medicines is favorable for patients who require 
specialized medications that are not commercially available, as they would otherwise not have access to suitable treatment. However, 
if an FDA-approved drug is commercially available, the use of an unapproved compounded drug confers additional risk with no 
commensurate benefit. Published reports of independent testing by the FDA, state agencies, and others consistently show that 
compounded drugs fail to meet specifications at a considerably higher rate than FDA-approved drugs. Compounded sterile preparations 
pose the additional risk of microbial contamination to patients. In the last 11 years, three separate meningitis outbreaks have been 
traced to purportedly ‘sterile’ steroid injections contaminated with fungus or bacteria, which were made by compounding pharmacies. 
The 2012 outbreak has resulted in intense scrutiny of pharmacy compounding practices and increased recognition of the need to ensure 
that compounding is limited to appropriate circumstances. 
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Purpose of the Study 
The article aims to physico-chemical and economic 
considerations before compounding; factors and quality 
control issues; compounding support, training, chemical 
supplies, types of compounding (especially in hospital and 
ambulatory care compounding). It should aid to practice the 
extemporaneous preparation of basic and advanced 
formulations including pharmacopoeial and non-
pharmacopoeial formulations encountered in pharmacy 
practice, together with requisite documentation, labeling, 
packaging and counseling requirements. Along with this, they 
have to study the analysis of formulations and their 
components and relate these to the clinical performance of 
medicines. This will help them to investigate, evaluate and 
report the physical characteristics of formulations including 
release kinetics and relate these to quality control and 
preformulation requirements; relate the application of quality 
control, quality assurance and the principles of good 
manufacturing practice to regulation of medicine production in 
home and abroad. 
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Figure 1. Graphical Abstract 
 
Article Highlights: 
1. An estimate by FDA that 1-10% of all prescriptions require 
compounding was not supported by evidence data. 
2. In 2006, the FDA conducted a limited survey of 
compounded drugs revealed failure rate of 33%. 
3. In 2001, a Kansas City-based pharmacist was discovered 
to have adulterated 72 different drugs, including many 
oncology medications, to increase profits.  
4. Over the period 2008–2010, the Texas State Board of 
Pharmacy found an overall potency failure rate of 23% for 
compounded drugs 
5. Methylprednisolone injections from a single compounding 
pharmacy in the USA resulted in 137 cases of Aspergillus 
fumigatus meningitis and 12 deaths. 
6. Even where a given formulation has been shown to 
achieve suitable physical, chemical and microbiological 
stability, the bioavailability and palatability of the 
preparation may be unproven. 
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7. Ingredients, intended use, dosage, and method of 
administration, education, skill and expertise; proper 
equipment, supplies, chemicals the guidelines delineated 
in US pharmacopeia, necessary calculations and 
documentation; expected duration of therapy, physico-
chemical compatibility are the major considerations 
before compounding. 
8. Quality must be built-in to the preparation from the 
beginning steps to evaluating the final preparation. 
9. The use of an alternative route of administration (use of 
the rectal rather than the oral route) could also be 
considered if an appropriate formulation is available. 
 
Introduction 
The FDA defines traditional pharmacy compounding as the 
combining, mixing, or altering of ingredients to create a 
customized medication for an individual patient in response      
to a licensed practitioner’s prescription. The NABP                 
further describes compounding as the result of a practitioner’s 
prescription drug order based on the 
practitioner/patient/pharmacist relationship in the course of 
professional practice. Traditional pharmacy compounding plays 
a valuable role in providing access to medications for 
individuals with unique medical needs, which cannot be met 
with a commercially available product. For instance, a 
prescriber may request that a pharmacist compound a 
suspension for a pediatric or geriatric patient unable to swallow 
a medication in its commercially available form. In traditional 
pharmacy compounding, an individualized medicine is 
prepared at the request of a prescriber on a small scale. It is 
obvious that large scale manufacturers have very limited 
opportunity to customize dosage strength and dosage forms for 
a customer segment that is not substantially big enough due to 
economies of scale concept of business. Another major 
difference is that compounding pharmacies are not required to 
report adverse events to the FDA, whereas adverse event 
reporting is mandatory for manufacturers of FDA-regulated 
medications. Thus, adverse events associated with 
compounded drugs may be difficult to detect, particularly if the 
affected patients are widely scattered in different geographic 
areas. Registered and skilled pharmacists in practicing their art 
of compounding fills in this gap to meet individualized needs. 
Compounding has always been a basic part of pharmacy 
practice; the drugs, dosage forms, and equipment or 
techniques used are the variables. Pharmacists have unique 
knowledge and skills and are not duplicated by any other 
profession. Pharmacy activities to individualize patient therapy 
include compounding and clinical functions. Either function in 
the absence of the other results in placing pharmacy in a 
vulnerable position. It is important to entrust a pharmacist’s 
expertise to adjust dosage quantities, frequencies, and even 
dosage forms to enhance compliance. Pharmacy is a complex 
mixture of different practices and practice sites. No longer is 
pharmacy simply community pharmacy or hospital pharmacy. 
Pharmacy is diverse and offers many opportunities for those 
willing to look around, find their niche and practice pharmacy 
to meet the needs of their own community of patients. Most 
compounding pharmacists appear to be interested and excited 
about their practices. In fact, many pharmacists intimately 
involved in pharmaceutical care have now realized the 
importance of providing individualized patient care through the 
preparation of patient-specific products. Compounding 
pharmacy is not for everyone, but as it grows, it will provide an 
increasingly significant number of pharmacists the excitement 
and fulfillment of using their innovative and creative skills to 
solve patient problems. All components of a compounded 
product, that is the active ingredient and the excipients, are 
subject to quality standards set out in the Therapeutic Goods 
Act 1989, and are sourced from compounding supply 
companies that undertake rigorous quality-assurance testing. 
 
 
 
Figure 2. Rationale of Extemporaneous compounding 
(Source: Velpandian T., Das U.S. (2016) Extemporaneously 
Used Drug Formulations for Ocular Emergencies.  
In: Velpandian T. (eds) Pharmacology of Ocular 
Therapeutics. Adis, Cham 
 
Rationale of Extemporaneous Compounding 
An estimate by FDA that 1-10% of all prescriptions require 
compounding was not supported by evidence data. EP 
strategies in clinical studies requires 'fit-for-purpose' 
formulation design and preparation processes, as well as 
administration procedures that are safe, flexible, cost-effective, 
and simple to adapt by a compounding pharmacist at the 
clinical site. Many commercially available medications are not 
manufactured in suitable dosage forms for these special 
populations, e.g., liquid formulations for children and those 
who may be unable to swallow tablets. Additionally, when drug 
shortages occur or for the treatment of rare diseases, 
compounded products have a place in practice.  Examples of 
altered drug products include topical ointments, eye drops, 
solid or liquid oral dosage forms, and intravenous infusions. 
Compounding also has a place in veterinary practice, where 
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medicines may be altered to suit drug absorption, metabolism, 
and swallowing abilities of different species. The use of small-
scale compounded medications carries certain risks, as they are 
not assessed for product quality, stability, or efficacy. The 
importance of a collaborative, team-based approach to patient 
care and safety has been well established within the health 
field. The requirement for alternative medications and dosage 
forms may be determined by the patient’s general practitioner 
who prescribes the medication or other allied health 
professionals: a speech pathologist who identifies a swallowing 
difficulty, a physiotherapist applying ultrasound, which may 
interfere with transdermal drug delivery, or an occupational 
therapist identifying that a patient is unable to physically 
manipulate their current medication or its packaging. This 
highlights the importance for other members of the health care 
teams to have knowledge and understanding of compounded 
medications. Among elderly patients, the incidence of 
dysphagia is reportedly as high as 7%–13%, making utilization 
of available oral dosage formulations unfeasible or unsafe. 
Similarly, Canadian hospital pharmacists often encounter 
patients with oral, neck, or gastric cancer, which may make 
commercial solid dosage formulations impossible to use.  Based 
on pharmacists’ perspective, using more extemporaneous 
prepared products could also make sense economically. ‘The 
significant therapeutic improvement and some cost savings 
may be gained’ by the rational use of extemporaneously 
prepared medicines. Pharmacists that did not provide 
compounding service cited by the main reason as not receiving 
prescriptions that required compounding (63.6% of non-
compounder pharmacists). In about 33% of the compounded 
products, they indicated patient-specific reasons. In about 10% 
this reason concerned a strictly defined pharmaceutical care 
issues. Some researchers conclusively said that 73.2% 
pharmacists reported their goal in providing full pharmaceutical 
care to their patients was the most important motivator. The 
main reasons for the decision to provide compounding service 
were want to provide full pharmaceutical care to patients 
(73.8% of compounder pharmacist) and responding to requests 
by prescribers. Most community pharmacists (nearly 70%) 
accepted compounding as a component of pharmaceutical 
care. In most of the studies, major reasons stated by physicians 
for prescribing extemporaneous products were that they 
worked well for certain conditions and that the product was not 
available commercially [1-7]. 
 
Evaluation of the Need 
 Soluble or dispersible tablets may be a useful and 
convenient alternative to the preparation of liquid 
extemporaneous products. Some tablets can be 
dispersed or crushed and information on this aspect 
can be obtained from the Medicines Information 
Section within the healthcare setting.  In this case, the 
dose should be prepared and administered 
immediately. In general, compressed tablets or tablets 
which are scored or just film coated can be crushed 
whereas modified release tablets cannot.  
 If a particular medicine is not available as a liquid 
formulation, another medicine from the same 
therapeutic classification may well be used, such as 
the use of a less potent steroid rather than diluting a 
potent one.   
 Using a suitable preparation intended for a different 
route of administration, for example, using an 
injectable solution orally.   
 Use of a ‘specials’ preparation manufactured in 
licensed premises (Specials are medicines made in 
larger volumes by a licensed manufacturer) [7]. 
 
Considerations before compounding  
 Commercially availability of drug in dosage form, 
strength, and packaging 
 Ingredients, intended use, dosage, and method of 
administration concern 
 Education, skill and expertise to drug compounding 
 Proper equipment, supplies, chemicals and the 
guidelines delineated in us pharmacopeia 
 An alternative by which the patient will receive a 
benefit 
 Safety of the compounded product 
 Patient necessary storage facility, if required, 
 Necessary calculations to prepare the product 
 Necessary documentation to complete preparation 
 Literature reference that might provide information 
on use, preparation, stability, administration 
 Expected duration of therapy  
 Some basic quality control to check the product prior 
to dispensing (e.g., capsule weight variation, pH, visual 
observations) 
 Ingredient identity, quality, and purity 
 Corrective methods 
 Physico-chemical incompatibilities [5,6] 
 
Economic Considerations: The most significant factor which 
limits prescribing of compounded medicines was that patients 
did not want products due to these products were not covered 
by the national insurance. Furthermore, for doctors not 
prescribing these products, the major barrier to prescribing was 
their lack of knowledge of the products. Most responding 
doctors do not prescribe medications that require 
compounding because they lack trust in the quality of the 
compounded formulations. However, most of the doctors 
expressed a desire to learn more as shown in having access to 
information about the usefulness of extemporaneous products. 
There are at least two different economic considerations in 
making the decision to compound prescriptions; these include 
(a) pharmacist compensation and (b) health-care costs. The 
pricing of a compounded prescription should include 
consideration for pharmacodynamic and pharmacotherapeutic 
decision making, formulation expertise, time, and 
reimbursement of materials. Compounding prescriptions can 
be attractive professionally and financially. Compounding 
prescriptions can be a way of lowering the cost of drug therapy. 
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In some cases, it is less expensive for the pharmacist to prepare 
a specific prescription for the patient, which may mean the 
difference between the patient actually obtaining the drug or 
doing without it. If compounding a prescription results in a 
patient being able to afford the drug therapy, it must be 
considered. An interesting example involves the drug 4-
aminopyridine. Although physicians had been prescribing 
unapproved versions of the drug for up to 20 years, it was not 
until the drug was studied systematically that rare seizures 
were discovered as a potential side effect. In this case, the 
medical profession pushed for an approved version to be 
marketed, rationalizing that if a seizure occurred in the context 
of a patient taking an FDA-approved alternative [4-10]. 
 
Compounding Factors 
Stability: One key factor in compounding prescriptions is 
stability. The more common types of stability of which 
compounding pharmacists should be aware include chemical, 
physical, and microbiological. Whereas commercially 
manufactured products are required to possess an expiration 
date, compounded products are assigned a beyond-use date. 
There are numerous sources of information that can be used 
for determining an appropriate beyond-use date, such as 
chemical companies, manufacturers literature, laboratory data, 
journals, and published books on the subject. Generally, most 
pharmacists prepare or dispense small quantities of 
compounded products; recommend storage at room, cool, or 
cold temperatures; and use a conservative beyond-use date. 
For nonaqueous liquids and solid formulations (for which the 
manufactured drug product is the source of active ingredient) 
— The beyond-use date is not later than 25% of the time 
remaining until the product’s expiration date or 6 months, 
whichever is earlier. A USP or NF substance is the source of 
active ingredient— The beyond-use date is not later than 6 
months. For water-containing formulations (prepared from 
ingredients in solid form)—The beyond-use date is not later 
than 14 days when stored at cold temperatures. For all other 
formulations—The beyond-use date is not later than the 
intended duration of therapy or 30 days, whichever is earlier. 
These beyond-use date limits may be exceeded when there is 
supporting valid scientific stability information that is directly 
applicable to the specific preparation (i.e., the same drug 
concentration range, pH, excipients, vehicle, water content). 
For example, active ingredients containing an ester functional 
group, such as aspirin and penicillins, are susceptible to 
breakdown by hydrolysis, while those containing aldehyde or 
hydroxyl groups, such as testosterone and dopamine, undergo 
oxidative decomposition. A 10°C increase in temperature can 
result in a 2–5-fold faster rate of degradation. The instability of 
dapsone suspensions prepared in Oral Mix and stored at 25°C 
may be explained by a Maillard reaction between the sucrose 
in the vehicle and the amino groups of the dapsone. The results 
of this study have demonstrated the stability, for up to 90 days, 
of dapsone suspensions (2 mg/mL) prepared from commercial 
tablets in Oral Mix SF and stored at 5°C and 25°C or prepared in 
Oral Mix and stored at 5°C, in amber plastic bottles and amber 
plastic syringes. These suspensions should be shaken before 
use [2],[5],[6], [11], [12].  
 
 
Exhibit 1. Common degradation pathways of active drugs in compounded products* [2,5] 
Pathway Factors determining 
degradation rate 
Susceptible functional 
groups 
Examples 
Oxidation  Concentration of 
drug, temperature, 
catalysts, solvents, 
light and excipients  
Aldehydes, alcohols, 
phenols, alkaloids, 
unsaturated alkyl chains, 
carboxylic acids  
Paracetamol, progesterone, testosterone, quinine, 
oils (unsaturated fats) such as soybean and corn oil, 
essential fats, atorvastatin, atenolol  
(O2 dependent)  Esters, amides, lactones, 
ethers, lactams, imines, 
acetals, anhydrates, 
sulfonamides  
Aspirin, vigabatrin, norfloxacin, omeprazole, 
simvastatin (statins), baclofen, diphenoxylate, 
methylphenidate, lignocaine, sildenafil, penicillins, 
cephalosporins, diazepam, digoxin, heparin, captopril, 
hydrocortisone  
*Drug molecules with more than one functional group can be more easily degraded. In fact, many drugs contain more than one 
functional group, being susceptible to both oxidation and hydrolysis, e.g. atenolol (contains amide and alcohol groups) 
 
 
It is essential that the active ingredient does not interact with 
any excipients originating from the dosage form being crushed 
for reformulation (e.g. tablet lubricants and fillers), or from 
additives in the new formulation (antioxidants, preservatives, 
suspending agents, colourants, emulsifiers). Interactions with 
other ingredients can result in physical instability of the 
product, such as precipitation of the active drug or phase 
separation (‘cracking’) of a cream, affecting drug solubility, 
absorption and bioavailability. To minimize the risk of a 
compounded medicine degrading, short-term expiry dates are 
used (e.g. 28 days for oral and topical products, or 24 hours for 
parenteral formulations), unless stability studies have been 
conducted and indicate otherwise [2,5]. 
 
Potential Risks: FDA-approved drugs are made and tested in 
accordance with GMPs, which are federal statutes that govern 
the production and testing of pharmaceutical products. In 
contrast, compounded drugs are exempt from GMPs, and 
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testing to assess product quality is inconsistent. Unlike  
FDA-approved drugs, pharmacy-compounded products are not 
clinically evaluated for safety or efficacy. The NABP  
further describes compounding as the result of a  
practitioner’s prescription drug order based on the 
practitioner/patient/pharmacist relationship in the course of 
professional practice. In addition, compounded preparations 
do not have standard product labeling or prescribing 
information with instructions for safe use. Compounding 
pharmacies are not required to report adverse events to the 
FDA, which is mandatory for manufacturers of FDA-regulated 
medications. Some pharmacies engage in activities that extend 
beyond the boundaries of traditional pharmacy compounding, 
such as large-scale production of compounded medications 
without individual patient prescriptions, compounding drugs 
that have not been approved for use in the US, and creating 
copies of FDA-approved drugs. Compounding drugs in the 
absence of GMPs increases the potential for preparation errors. 
When compounding is performed on a large scale, such errors 
may adversely affect many patients. Published reports of 
independent testing by the FDA, state agencies, and others 
consistently show that compounded drugs fail to meet 
specifications at a considerably higher rate than FDA-approved 
drugs. Compounded sterile preparations pose the additional 
risk of microbial contamination to patients. In the last 11 years, 
three separate meningitis outbreaks have been traced to 
purportedly ‘sterile’ steroid injections contaminated with 
fungus or bacteria, which were made by compounding 
pharmacies. US-FDA and the NICHD, have worked together to 
develop product labeling for pediatric patients for existing and 
new drug molecules coming to the market, if the drug has been 
or could be used in children. When compared to GMPs, the 
manufacturing standards required by FDA for commercial 
products, there are multiple recognized deficiencies inherent in 
extemporaneous formulation-compounding suitable for 
pediatric patients [11, 13]. 
 
 
Exhibit 2. Why Is Off-Label Use of Drugs in Children Still a Problem? [13] 
 Lack of specifications required for component development by compounding pharmacies. 
 No onsite testing of active ingredients and excipients for purity, potency, content and stability. 
 No onsite specifications or testing of product containers and closures. 
 Site-to-site variations in compounding procedures, equipment, and the degree of product 
handling/manipulation. 
 Lack of environmental control, which might lead to unintentional contamination and generation of degradation 
products due to inconsistent exposure to light, temperature and processing controls. 
 Lack of testing of finished products for purity, potency, content or stability. 
 Stability data for establishing expiry dates of compounded products are derived from published data, where 
preparation methods likely vary from local methods, or are simply default expiry periods defined by regional 
pharmacy regulations and “best practices”. 
 Published preparation methods provide only a portion of the information needed to consistently prepare a 
stable potent final product. 
 Limited options available to mask bad-tasting active ingredients. 
 The dose administration technologies used such as droppers, syringes, scoops, spoons, etc., vary between sites 
and between prescription fills. 
 Weak regulatory oversight. 
 
 
Quality Control: One of the fastest growing and most important 
areas of pharmaceutical compounding is that of quality control. 
Quality must be built-in to the preparation from the beginning 
steps to evaluating the final preparation. The extent of quality 
control applied to a product should be proportionate with the 
level of risk the finished product could pose to the patient and 
should be judged on a case by case basis. Even where a given 
formulation has been shown to achieve suitable physical, 
chemical and microbiological stability, the bioavailability and 
palatability of the preparation may be unproven. Consideration 
should be given to the individual patient’s age and condition, 
whether the product will be ingested or used topically, as well 
as the potency of, and risk posed by, the active substances 
and/or excipients. Where it is not practical to carry out this 
testing (e.g. due to the batch size, urgency, etc.), other suitable  
 
 
methods should be implemented to ensure that the 
appropriate quality is achieved, in accordance with the risk 
assessment carried out. At a minimum, the starting materials 
and finished product should be examined visually before supply 
to a patient. There are several quality control tests that can be 
done within the pharmacy and others can be sent to a contract 
laboratory. The following quality control tests can be 
considered for the respective dosage forms. 
 
 Oral and topical liquids (solutions, suspensions, 
emulsions): Weight/volume, pH, specific gravity, active 
drug assay, globule size range, rheological 
properties/pourability, physical observation (color, clarity), 
physical stability (discoloration, foreign materials, gas 
formation, mold growth). 
Review PHARMACY PRACTICE 
 
http://z.umn.edu/INNOVATIONS                         2019, Vol. 10, No. 4, Article 3                        INNOVATIONS in pharmacy 
                                                                             DOI: https://doi.org/10.24926/iip.v10i4.1660 
6 
 
 Hard Gelatin Capsules: Weight-overall average weight, 
weight individual weight variation, dissolution of capsule 
shell, disintegration and/or dissolution of capsule contents, 
active-drug assay, physical appearance (color, uniformity, 
extent of fill, locked), physical stability (discoloration, 
changes in appearance). 
 Ointments, Creams and Gels: Theoretical weight 
compared to actual weight, pH, specific gravity, active drug 
assay, physical observations (color, clarity, texture-surface, 
texture-spatula spread, appearance, feel) and rheological 
properties. 
 Suppositories, Troches, Lollipops and Sticks: Weight, 
specific gravity, active drug assay, physical observation 
(color, clarity, texture of surface, appearance, feel), 
melting test, dissolution test, physical stability. 
 Parenteral preparations: Weight/volume, physical 
observation, pH, specific gravity, osmolality, assay, color, 
clarity, particulate matter, sterility, pyrogenicity [5,6], [14]. 
 
Compounding Support: Numerous agencies, companies, 
organizations, etc., are available to assist pharmacists in 
compounding. Information, chemicals, supplies, and 
equipment are readily available. Chemical and supply 
companies have increased in size and number in recent years 
and many provide information on compounding, 
incompatibilities, and stability. Specialty compounding 
organizations have developed over recent years and generally 
provide full-line services and products to the compounding 
pharmacist. Many national organizations provide continuing 
professional education programs in both non-sterile and sterile 
compounding. These entities provide services to compounding 
pharmacists ranging from selling only compounding aids to 
providing only chemicals. Others offer additional services to 
include formulas as well as consulting expertise by telephone 
or via the internet. This service can assist in the process of 
compounding a particular product that may be difficult. 
 
 
 
Exhibit 3. MHRA (2007)  
in the context of extemporaneous preparation [14] 
 Extemporaneously prepared medicines should be 
formulated and prepared in compliance with current 
legal requirements and standards.  
 Preparation and quality control arrangements are to be 
documented and in compliance with current GPP 
requirements.  
 All products prepared should be quality suitable for 
their intended use   
 Products are released for patient use only by a 
pharmacist.  
 Documentation and records should comply 
recommendations in this guidance document. 
 
 
 
Training and Experience: Pharmacists involved in upgrading 
and increasing the traditional aspects of extemporaneous 
compounding need to keep current with all the new tools of 
their trade, retrieve the old from storage, and put in a bit of 
practice using their scientific background and their art before 
they will be comfortable in exhibiting their skills. The 
pharmacist must ensure that the staff, facilities and systems in 
place are capable on a day-to-day basis of providing an 
adequate quality service able to meet the needs of patients. 
There should be an adequate number of competent personnel 
at all times. All staff involved in extemporaneous preparation 
must receive training Appropriate to their role. Typically, this 
will: (a) provide them with knowledge in good extemporaneous 
preparation practice, local practices including health and 
safety, formulation, expiry periods and quality assurance 
appropriate to the level of involvement, assessment of risk and 
medication error potential, the pharmacy, its products and 
services provided (b) demonstrate competency in the 
necessary extemporaneous preparation skills and 
pharmaceutical calculations and dilutions. During training, staff 
must be carefully supervised and checked and trainees must 
understand the limits of their responsibilities. When 
considering providing additional services of compounding in an 
institution, pharmacists should not expect that this will change 
a great deal of their practice in time consumed for 
compounding.  A written training program should be available 
and completion of training should be documented. This applies 
to all personnel working in the preparation area, including 
those not directly involved in preparation processes (e.g. 
cleaning staff). [14]. 
 
Equipment: The equipment needed will be determined by the 
type and extent of the services one chooses to provide. Many 
pharmacies already have clean air environments (e.g., laminar 
air flow hoods, isolation barrier systems) where aseptic 
compounding of sterile solutions is performed. These same 
units can be used to compound other sterile preparations such 
as eye drops. A balance, preferably electronic, is essential. 
Ointment slabs (i.e., pill tiles), along with spatulas of different 
types and materials, should be purchased. A few mortars and 
pestles (i.e., glass, ceramic, plastic) and some glassware should 
be secured. A policy for the segregation of specific equipment 
for certain product types, including cytotoxic drugs and external 
products, should be available; this should take into account 
local COSHH assessments. Equipment should be calibrated and 
validated to demonstrate satisfactory performance. Measures 
should be calibrated for specific volumes and should have 
levelling lines. Glassware should be inspected regularly, before 
and after each use, for chips and cracks, and replaced as 
necessary. Consideration should be given to the merits of other 
materials. Stainless steel of a suitable grade is a good material 
but care must be taken with some agents as it is susceptible to 
oxidation. Plastics are susceptible to surface scratches and 
stains. The accuracy of balances should be checked on a regular 
basis and records of this process maintained. It may not be 
necessary to buy a roomful of equipment, but one should 
Review PHARMACY PRACTICE 
 
http://z.umn.edu/INNOVATIONS                         2019, Vol. 10, No. 4, Article 3                        INNOVATIONS in pharmacy 
                                                                             DOI: https://doi.org/10.24926/iip.v10i4.1660 
7 
 
purchase what is needed to start the service and should build 
on it as the service grows and expands to different arenas. 
Much of the equipment used today in compounding has 
changed. Today, electronic balances are used more often than 
torsion balances; micro-pipets are commonplace; and ultra-
freezers are sometimes required in addition to standard 
refrigerator freezers. This area is constantly changing and the 
compounding pharmacist should be aware of the available 
technology to prepare accurate and effective prescriptions. 
Becoming acquainted with the local representative for a 
laboratory supply company is helpful [2], [6], [14-19]. 
 
Environment: A separate area for traditional compounding is 
recommended, rather than simply cleaning off a small area of 
the dispensing counter. The compounding pharmacist needs a 
clean, neat, well-lit and quiet working area. If aseptic 
compounding is considered, a clean air environment (e.g., 
laminar air flow hood, isolation barrier system) should be used. 
The actual facility to be used depends on the level and volume 
of compounding to be done. Extemporaneous compounding 
takes place in community and hospital pharmacies. There are 
usually specialist compounding pharmacies in major towns and 
cities, but any pharmacy may undertake compounding as long 
as they have appropriate facilities according to state-based 
legislation (e.g. allocated clean bench, specific compounding 
equipment). There should be a dedicated facility/room for 
extemporaneous preparation. However, for pharmacies 
preparing small quantities of a limited range of products for 
immediate dispensing then a designated area or temporarily 
designated area is permissible. The area must be clearly 
demarcated during preparation. Measures must be taken to 
reduce any risk of cross- contamination. Only one product 
should be handled at a time. Premises and equipment should 
be easy to clean. Following maintenance or repair, thorough 
cleaning and, where appropriate, disinfection should take 
place. Environmental conditions, including temperature, 
humidity and lighting, must be adequate to permit safe and 
comfortable preparation of medicinal products to limit the 
degradation of ingredients. Facilities should be laid out in a way 
to provide adequate space for the activities undertaken. Work 
should flow logically between working areas without the risk of 
product cross- contamination. Complex compounding is 
performed in a pressurized clean room using a laminar flow 
cabinet, cytotoxic drug safety cabinet or an isolator. Many 
public and private hospitals maintain large aseptic 
compounding facilities to provide individualized dosing or 
commercially unavailable formulations.  Areas and equipment 
should be cleaned effectively with a suitable detergent before 
and after use. Equipment should be rinsed with an appropriate 
grade of water after washing (potable or sterile water for 
irrigation/injection) and then dried. Critical surfaces should be 
effectively sanitized with a suitable agent such as 70% alcohol 
before use. Sinks should be available for washing up of 
equipment, with separate facilities for handwashing. Sinks 
should be a suitable distance away from the preparation areas 
to reduce the risk of microbial contamination from water 
splashes. Washing and cleaning activities should not 
themselves be a source of contamination. All equipment should 
be visibly clean prior to use. Ensure that all residues of cleaning 
agent have been removed Containers and lids should be 
checked to ensure that they are clean and dry before use. 
Adequate pest control measures should be taken. [6], [10], [19] 
 
Formulas: Consistency of the compounded product is 
important. Formulas should be developed or obtained and tried 
to assure that each time an extemporaneous product is 
prepared, the methods used, ingredients added, and the order 
of steps is documented. This accomplishes three things. First, it 
provides the methodology for each person involved or 
requested to provide such service the information necessary to 
do so properly. Second, it provides consistency from batch to 
batch. Third, if the product does not turn out the way expected, 
a stepwise methodology exists for reviewing and determining 
what happened and if revisions and improvements are needed 
[6], [15]. 
 
Chemicals and Supplies: If one is going to prepare a topical 
product, a vehicle (e.g., cream, ointment, gel) and the active 
ingredients (e.g., either finely ground product from an available 
tablet or injection or pharmaceutical-grade chemicals) would 
be required. One needs proper dispensing containers for the 
medication. In short, a relationship with providers that carry 
chemicals and supplies is important. Pharmacists have been 
using chemicals and other materials for prescription 
compounding throughout history. In the past, these chemicals 
and materials have been obtained from natural products, raw 
materials, and household ingredients. Today, compounding 
pharmacists use chemicals from various reliable commercial 
sources, depending on their availability [9], [15-18].  
 
Documentation: These give processing, packaging and release 
instructions. For products regularly prepared, master 
documents which combine the specification and product 
specific instructions should be produced and independently 
checked. Alternatively, a simple final product specification may 
be produced in addition to the master document. Master 
documents should be clear and detailed and should have a 
standardized style within any one pharmacy. Simple stepwise 
instructions for preparation, along with any specific notes or 
cautions (e.g. COSHH requirements) should be included on the 
master document for each product. A record should be kept of 
the key stages of processing, packaging and release of products 
to provide an audit trail of the quality relevant facts of the 
history of an extemporaneous product during preparation. This 
is normally achieved by completion of an individual worksheet, 
usually by photocopying the master document. Worksheets will 
vary for each pharmacy but should include: the name and 
formula of the product, and the source of the formula; a unique 
identification number to enable traceability; the manufacturer, 
batch numbers of each starting material (or QC reference 
number); the date of preparation etc. Labels must comply with 
all statutory and professional requirements, and should include 
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the following information: the name of the product, and  
where necessary the nature of the salt and any waters of 
crystallization; quantity and strength of active ingredients; the 
pharmaceutical form etc. [6], [20]. 
 
Types of Compounding 
Active pharmaceutical ingredients can be incorporated into a 
wide array of products including creams, eye drops, nasal 
sprays, oral dosage forms or intravenous infusions. In Australia, 
products may be classified into simple or complex 
compounding (Table 1). Simple compounding can be 
performed by any pharmacist and is a core competency of 
pharmacy training. Complex compounding requires additional 
training and evidence, as described by the Pharmacy Board of 
Australia’s guidelines on compounding. Finland, Italy, and 
Scotland prepared mainly powder, while Belgium, Croatia, 
France, and Switzerland prepared mainly capsules. Practice in 
Germany, Spain, and Slovenia involved preparation of a less 
well-defined combination of liquid, powders, and capsules. 
 
Table 1. Classification of simple versus complex compounding [5] 
Type  Explanation  Examples  
Simple  All pharmacists have training during their 
undergraduate degree to prepare these 
products.  
Involves well-established preparations 
published in reputable literature, e.g. the 
Australian Pharmaceutical Formulary and 
Handbook, or formulae for which some data 
are available regarding quality, stability, 
safety, efficacy and rational design.  
Topical creams, ointments, lotions, gels, e.g. steroids, 
hormones, coal tar, cholestyramine. 
Oral liquids (solutions, suspensions, emulsions, mixtures, 
elixirs), tinctures, e.g. omeprazole suspension. Capsules, 
tablets, powders, e.g. ethinylestradiol capsules. 
Suppositories, pessaries, e.g. paracetamol, clotrimazole  
Complex  Pharmacists require further postgraduate 
training in association with self-assessment 
of relevant competencies and 
documentation of the specific 
competencies in a continuing professional 
development plan. Specialized facilities 
(sterile room with positive pressure) and 
equipment (laminar flow isolator, dry heat 
sterilization oven) are also required.  
Parenterals, e.g. morphine, clonidine. Ingredients with a 
safety hazard, e.g. cytotoxics, hormones  
Single unit micro-dose (<25 mg of drug or no more than 
25% w/v of a dosage form), e.g. naltrexone. Modified-
release dosage forms, e.g. levothyroxine (T4), 
progesterone capsules  
Ophthalmic preparations, e.g. phenylephrine, 
tropicamide, ciprofloxacin  
 
Ambulatory-Care Compounding: If individuals can walk, they 
are considered mobile or ambulatory (i.e., they are not 
bedridden). Consequently, most pharmacists are involved in 
ambulatory care, and most ambulatory patients are 
outpatients. Actually, the term can also be applied to home-
care patients and even institutionalized patients who are 
mobile. One general characteristic of ambulatory patients is 
that they are generally responsible for obtaining their own 
medication, storing it, preparing it (if necessary), and taking it. 
It seems almost incongruous that in health care today as we 
become more aware that patients are individuals, respond as 
individuals, and must be treated as individuals that some 
health-care providers appear to be grouping patients into 
categories. They are grouped in categories for treatment, for 
reimbursement from a third party, or for determining levels of 
care in managed-care organizations and using fixed-dose 
products provided by pharmaceutical manufacturers that are 
available because the marketing demand is sufficiently high to 
justify their manufacture and production. Why should the 
availability or the lack of availability of a specific economically 
profitable commercially available product dictate the therapy 
of a patient? Pharmacists have an opportunity to extend their 
activities in patient care as the emphasis continues to shift from 
inpatient care to ambulatory care. Ambulatory care, however, 
is so diverse and involves so many disciplines that sometimes it 
is difficult to understand it; and, it changes rapidly. Also, 
ambulatory care could generally encourage a team approach to 
health improvement, prevention, health maintenance, risk 
assessment, early detection, management, curative therapy, 
and rehabilitation. Ambulatory care offers various 
opportunities for individualizing patient care through 
pharmaceutical compounding. In fact, it is the area where most 
compounding pharmacists’ practice. Pharmacists’ roles in 
ambulatory care patients can include, among others 
 
• Dispensing 
• Compounding 
• Counseling 
• Minimizing medication errors 
• Compliance enhancement 
• Therapeutic drug monitoring 
• Minimizing expenditures 
 
Most reimbursement for ambulatory patients comes from the 
dispensing or the compounding process. Little financial 
consideration is given to counseling, minimizing medication 
errors, compliance enhancement and therapeutic monitoring. 
However, these activities are important and should be 
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performed. Because of the unique nature of compounded 
medications, counseling is an absolute must for these patients. 
From the above discussion of the activities of ambulatory care 
pharmacists, it should be evident that extemporaneous 
compounding can be vitally important in ambulatory patient 
care [6], [18-21] 
 
Hospital Pharmacy Compounding: The ever-present 
responsibility of the health-care industry is to provide the best 
available care for the patient, using the best means to do so, 
and providing that care in a conducive environment. This must 
be sufficiently economical to not put the institution in jeopardy 
of being unable to continue to provide the services to the 
community they serve. This requires cooperation on the part of 
the hospital administration, the medical staff, and the 
employees (nurses and pharmacists in particular as regards to 
medication usage) and must involve the patient. One of the 
effective means by which hospitals, and therefore hospital 
pharmacies, can meet these challenges is to consider expanding 
extemporaneous compounding services within the hospital 
pharmacy. Pharmaceutical care and pharmaceutical 
compounding can provide cost savings to the hospital while 
providing needed options to the physician through problem-
solving approaches and stimulating the hospital pharmacist 
through new challenges that allow the expression of both their 
skills and their art [15], [22,23] 
 
Veterinary Compounding: The first symposium on veterinary 
compounding was a significant forum for discussion by experts 
and was a pivotal point in the history of veterinary 
compounding, occurring in September 1993. the meeting was 
important because it assembled an impressive group of experts 
on veterinary compounding, who then set about explaining and 
defining the roles of the veterinarian and the pharmacist [24]. 
 
Nuclear Pharmacy Compounding: Nuclear pharmacy is a 
specialty practice of pharmacy that has been defined as a 
patient-oriented service that embodies the scientific 
knowledge and professional judgment required for improving 
and promoting health through assurance of the safe and 
efficacious use of radioactive drugs for diagnosis and therapy. 
Radioactive drugs, commonly referred to as 
radiopharmaceuticals, are a special class of drugs that are 
regulated by the FDA. They are unique in that they contain an 
unstable nuclide (radioactive nuclide) as a part of the 
compound designed to localize in an organ or tissue. Since 
radiopharmaceuticals are radioactive, the Nuclear Regulatory 
Commission or a similar state agency is involved in regulatory 
matters relevant to radiopharmaceuticals [25-27]. 
 
Risk Management 
Legal Background: Pharmacists must comply with all legislation 
relevant to the practice of pharmacy in the jurisdiction where 
the practice occurs. Failure to practice in accordance with these 
requirements may give rise to action by one or more 
responsible authorities. These matters may then be referred to 
the Board for appropriate action under the National Law or law 
of a co-regulatory jurisdiction.  Non-compliance with these 
guidelines and the practice standards and guidelines relevant 
to compounding may also be notified directly to the Board for 
appropriate action under the National Law or law of a co-
regulatory jurisdiction. Non-compliance may be reported by an 
individual lodging a notification form, or through other means 
such as notification of outcomes of audits carried out by a 
state/territory pharmacy premises regulatory authority or 
responsible body [5].   
 
 
 
Exhibit 4. Examples of Pre-1938 Drugs That Remained on the Market as Unapproved Drugs [15] 
Acetaminophen, codeine phosphate, and caffeine capsules and tablets 
Amobarbital sodium capsules 
Amyl nitrate inhalant 
Chloral hydrate capsules, syrup, and suppositories 
Codeine phosphate injection, oral solution, and tablets 
Codeine sulfate tablets 
Colchicine injection and tablets 
Digitoxin tablets 
Digoxin elixir and tablets 
Ephedrine sulfate capsules and injection 
Ergonovine maleate injection and tablets 
Ergotamine tartrate tablets 
Hydrocodone bitartrate tablets 
Hydrocodone bitartrate, aspirin, and caffeine tablets 
Hydromorphone hydrochloride suppositories 
Levothyroxine sodium for injection 
Morphine sulfate oral solution and tablets 
Nitroglycerin sublingual tablets 
Opium tincture 
Oxycodone tablets 
Oxycodone hydrochloride oral solution 
Paregoric 
Phenazopyridine hydrochloride tablets 
Phenobarbital capsules, elixir, and tablets 
Phenobarbital sodium injection 
Pilocarpine hydrochloride ophthalmic solution 
Potassium bicarbonate effervescent tablets for oral 
solution 
Potassium chloride oral solution 
Potassium gluconate elixir and tablets 
Potassium iodide oral solution 
Salsalate capsules 
Sodium fluoride oral solution and tablets 
Thyroid tablets 
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Alternatives to extemporaneous preparation 
 Therapeutic substitution: The use of a licensed medicine 
from the same therapeutic classification should be 
considered and may provide a better clinical option than 
the use of an extemporaneously prepared medicine which 
has limited data to support its formulation and stability. 
The use of a less potent steroid rather than diluting a 
potent agent is an example where a therapeutic alternative 
may eliminate the need for an extemporaneous 
preparation. There are great opportunities for oncology 
pharmacists, as well as community pharmacists, as a 
resource for educating and monitoring patients receiving 
oral chemotherapy to ensure dosing accuracy, safe 
administration, and proper disposal of hazardous drugs. 
Oncology pharmacists face a constant challenge with 
patients who cannot swallow oral anticancer drugs, making 
extemporaneous oral liquid preparation a requirement. 
Improper extemporaneous preparation of these agents, 
especially with the traditional chemotherapy with a narrow 
therapeutic index, may increase the risk of over- or under-
dosing [28]. 
 Use of an imported product: The preparation selected 
should be licensed for use in a country with equivalent or 
similar licensing arrangements and regulatory standards to 
the UK (e.g. EU, Canada, Australia). This will provide the 
requesting pharmacist with assurance that the quality, 
safety and efficacy of the medicine have been reviewed by 
a competent regulatory authority. Although clinicians do 
not doubt the efficacy and utility of captopril in managing 
children with heart failure, concerns exist about optimal 
dosing schedules and toxicity. This formulation is licensed 
in the Bristol–Myers Squibb, Australia, but was not 
available in the UK [29]. 
 Use of a `Special' manufactured in a MHRA licensed unit: 
The benefit of purchasing a ‘Special’ is that the product 
should be made to a validated formula with supporting 
stability data in accordance with the principles of GMP. 
Licensed ‘Specials’ units are regularly inspected by the 
MHRA to ensure these principles are upheld. However, the 
purchasing pharmacist will still need to review the 
supporting documentation (e.g. specification, Certificate of 
Analysis/Conformity, BSE/TSE statement) to assess 
whether the product is of appropriate quality. Information 
on Specials manufacturers is available in the BNF. Specials 
may be used to meet a variety of patient needs, for 
example, for babies, children and older people, and in 
specific areas such as dermatology and palliative care [30].  
 Use of soluble or dispersible tablets: This practice presents 
fewer health and safety risks than crushing tablets, which 
can expose the carer to potentially harmful dusts via 
inhalation. When dispersing tablets, the dose should be 
prepared and administered immediately, as stability 
cannot be guaranteed. It should be noted that slow or 
modified release preparations should not be used in this 
manner. If the active is not soluble, it can lead to inaccuracy 
of dosing through a lack of dose uniformity and 
reproducibility. This is a major consideration when no 
suspending agents are used, especially when the person 
administering the dose is inexperienced and the dose is 
small [31]. Milk has been explored as a vehicle in liquid 
formulations showing potential for solubilizing drugs while 
maintaining the stability of the emulsified vehicle [32]. 
 Cutting tablets: Tablets cannot be cut with great accuracy 
of dose and research suggests that the variability may 
range from 50% to 150% of the desired dose even when 
using commercially available tablet cutters.  
 Use of a preparation intended for a different route: The 
use of a suitable preparation intended for a different route 
of administration can sometimes be a practical alternative; 
for example, the use of an injection solution orally, or an 
oral solution rectally. However, this practice has its own 
inherent risks and the pharmacist should ensure that the 
presentation used will be absorbed by this route and that 
it will be tolerated by the patient. When using an injection 
by the oral route, consideration should be given to the 
possibility of rapid absorption and elevated peak levels, the 
potential for rapid drug degradation due to exposure to 
gastric acid and problems with first-pass metabolism. The 
pH of an injection should also be considered, as extremes 
of pH can adversely affect the gastric mucosa [20]. 
 
Risks associated with extemporaneous preparation 
 Formulation failure: An insoluble drug suspended in a 
suitable vehicle may be less susceptible to drug 
degradation, but may settle out of the suspension over 
time, leading to sedimentation and caking. In this state, 
there will be a higher concentration of drug at the bottom 
of the bottle than at the top. In 2006, the FDA conducted a 
limited survey of compounded drugs. Of 36 samples tested 
by the FDA, 12 failed at least one quality test, for a failure 
rate of 33%. Further, oral hormone dosage forms 
containing multiple active ingredients showed poor 
content uniformity, with random variation in all three 
active ingredients from capsule to capsule [8], [20]. 
 Microbial contamination: The choice of preservative for a 
formulation needs to take into account a number of factors 
including pH, physical compatibility and the intended 
patient group. Unpreserved preparations should be stored 
in a refrigerator and assigned a short shelf-life to limit 
microbial growth. A maximum shelf-life of 7 days at 2–80C 
should be assigned to unpreserved oral liquid preparations 
unless sufficient validation work has been carried out to 
support an extended shelf-life. Essential macronutrients 
and micronutrients infused via PN solutions are an 
essential part of the care of infants and children who 
cannot or should not be fed enterally. Infants and children 
require a greater amount of fat in their diet than do adults 
to support growth and development. The use of IVFE 
provides a concentrated source of calories and prevents 
the development of essential fatty acid deficiency in 
neonates fed exclusively via the parenteral route. The AAP 
recommends IVFE doses of up to 3 g/kg/day 
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(approximately 30 kcal/kg/day) for use in infants. A variety 
of microorganisms have been found in residual IVFE after 
completion of the infusion [33]. Microorganisms could 
potentially be introduced during reformulation of non-
sterile products. For example, if Candida albicans is 
inadvertently introduced into freshly prepared multi-dose 
citric acid solutions that are to be used orally for cough 
reflex testing, immunocompromised individuals could 
become infected. Regular monitoring of the environment, 
equipment and procedures is essential to ensure quality 
and sterility is maintained. The consequences of failure can 
be catastrophic, for example methylprednisolone 
injections from a single compounding pharmacy in the USA 
resulted in 137 cases of Aspergillus fumigatus meningitis 
and 12 deaths [2]. 
 Calculation errors: Common calculation errors associated 
with extemporaneous preparation include errors when 
converting units from one to another (e.g. milligrams to 
micrograms, conversions from weight in volume to 
millimoles). Dangers of potent ingredients and calculation 
errors, particularly where the strength of one or more 
ingredient is stated in a historical or non-standard fashion. 
Similar reports have originated from the US, with the death 
of a child from a super-potent imipramine liquid, and a five-
year-old child who received a 1,000-fold overdose of 
clonidine. Problems can also arise when doses can be 
prescribed as free base or salt, leading to potential 
calculation errors when making and administering 
preparations (e.g. two-fold errors if caffeine citrate is 
confused with caffeine base).  Some of these errors have 
been attributed to inconsistent labelling approaches, for 
example, strengths expressed per millilitre or per 5ml 
spoonful. Clinical pharmacists in pediatrics and 
neonatology help in dose calculation and dosage form 
modification. The increased need for calculations and 
dilutions of pediatric medicines, and a requirement to 
adjust dose of an individual patient based on age, 
gestational age, weight and surface area, provide a greater 
opportunity for a clinical pharmacist in medication 
management process. They can help to prepare 
pediatric/neonatal formulary [34], [41]. 
 Starting materials: Care should also be taken with the use 
of cariogenic sugars (e.g. sucrose) in pediatric formulations 
as it has been associated with dental cavities. It is therefore 
important to list all such excipients on the product label so 
that end-users are made aware of their presence in the 
formulation. In a 2004 published analysis sponsored by STD 
Pharmaceuticals, all samples purchased from three 
compounding pharmacies failed content testing for a 3% 
sodium tetradecyl sulfate solution for injection (range 
2.59–3.39). Significant concentrations of the contaminant 
carbitol were found to be present in samples from all three 
sources (0.33–4.18), suggesting possible use of a non-
pharmaceutical grade chemical [35]. 
 
 Patient acceptability issues: Consideration should be given 
to the palatability and presentation of oral liquid medicines 
as there is a good argument that taste is crucial to achieving 
good compliance in children, especially for the treatment 
of longstanding conditions such as in cardiology. 
Extemporaneously prepared oral drug formulations can 
also be plagued by poor palatability characteristics which 
can compromise patient adherence. This lack of child-
friendly formulations affects 40% of the global population, 
subjecting pediatric patients to avoidable adverse drug 
events, reduced compliance with medication regimens, 
limited access to new medications, and prolonged 
treatable illnesses. The pressing need for child-friendly, 
palatable medications suitable for administration to both 
infants and young children has been stressed (through 
regulatory guidance) by both the European Medicines 
Agency and the US FDA. Prednisone is a bitter-tasting 
corticosteroid used for its anti-inflammatory and 
immunosuppressant effects to treat a wide variety of 
conditions in both adults and children. For pediatric 
patients, an alternative form of administration can be 
produced by crushing solid oral prednisone formulations in 
order to avoid swallowing difficulties and/or achieve 
weight-based dosing. This approach, however, creates 
extremely poor taste and mouth feel properties which are 
objectionable to pediatric patients. While these limitations 
can be somewhat mitigated by the use of proprietary oral 
liquid formulations of prednisone, such products still retain 
their profoundly bitter taste characteristics. It is estimated 
that approximately half of children refuse to take even a 
liquid form of prednisone, with the large majority of those 
reporting bad taste as the single major reason for non-
compliance. Efforts to mask flavors using sweetening 
agents, coatings, agglomeration, or microencapsulation 
often result in poorly-controlled, heterogeneous particle 
size distributions that result in a gritty or granular mouth 
feel and can provide ineffective taste masking, 
characteristics that may also compromise patient 
acceptance. The design of an ideal paediatric formulation 
needs to consider the following factors: (i) producing 
minimal impact on the lifestyle of the child, manifesting as 
the lowest dosage frequency and a palatable product, (ii) 
provision of individualized dosing or dose banding 
appropriate for effective therapy, (iii) sufficient 
bioavailability, (iv) non-toxic excipients in the formulation, 
(v) convenient and reliable administration and (vi) robust 
production process at minimal cost [20], [36-39]. 
 Health and safety risks: When handling hazardous 
products, units should be equipped with suitable 
containment devices and systems should be put in place to 
eliminate the risk of cross-contamination. 
 Therapeutic risks and clinical consequences: Any 
inaccuracy of dosing associated with medicines that have a 
narrow therapeutic index can lead to significant morbidity, 
whether due to under-dosing leading to treatment failure 
or overdosing leading to toxicity. By contrast, any 
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inaccuracy of dosing associated with drugs with a wide 
therapeutic index may have little or no impact on the 
therapy. 
 Associated clinical risk factors: The majority of patients 
receiving extemporaneously prepared products, in 
particular oral liquid medicines, tend to be from vulnerable 
patient groups (e.g. neonates, children, stroke victims) who 
are either unaware of ill-effects associated with their 
treatment or who cannot communicate with their clinician. 
Coupled with this, extemporaneous preparations may not 
be routinely identified as high-risk therapies by 
pharmacists and therefore such treatments are not 
commonly given the level of scrutiny and close monitoring 
they require. Therefore, when embarking on the use of an 
extemporaneously prepared product, the pharmacist 
should ensure that systems are in place to monitor the 
effectiveness of the therapy [20]. 
 
 
 
Exhibit 5. Extemporaneous preparation or compounding standards as set out in the Medicines [44] 
 A product is extemporaneously prepared only when there is no product with a marketing authorization available and 
where you are able to prepare the product in compliance with accepted standards. 
 Staff involved are competent to undertake the tasks to be performed.  
 The requisite facilities and equipment are available. Equipment must be maintained in good order to ensure that 
performance is unimpaired, and must be fit for the intended purpose.  
 The professional associate (Pharmacist) is satisfied as to the safety and appropriateness of the formula of the product.  
 Ingredients are sourced from recognized pharmaceutical manufacturers and are of a quality accepted for use in the 
preparation and manufacture of pharmaceutical products. Where appropriate, relevant legislation must be complied 
with.  
 Particular attention and care are paid to substances which may be hazardous and require special handling techniques.  
 The product is labelled with the necessary particulars, including an expiry date and any special requirements for the safe 
handling or storage of the product.  
 If you are undertaking large-scale preparation of medicinal products, all relevant standards and guidance are adhered 
to.  
 Records are kept for a minimum of 2 years. The records must include: the formula; the ingredients; the quantities used; 
their source; the batch number; the expiry date; where the preparation is dispensed in response to a prescription, the 
patient’s and prescription details and the date of dispensing; the personnel involved, including the identity of the 
pharmacist taking overall responsibility. 
 
 
 
Risk Management 
The European Pharmacopoeia monograph on Pharmaceutical 
Preparations specifies the necessity for tests to be applied to 
particular dosage forms, as described in their respective dosage 
form monographs, which are also applicable in the case of 
extemporaneously prepared products. The requirements on 
testing in the European Pharmacopeia monograph deal with 
the appearance of products, identity and purity tests, 
uniformity and reference standards. The extent of quality 
control applied to a product should be proportionate with the 
level of risk the finished product could pose to the patient and  
 
should be judged on a case-by-case basis. Consideration should 
be given to the individual patient’s age and condition, whether 
the product will be ingested or used topically, as well as the 
potency of, and risk posed by, the active substances and/or 
excipients. Where it is not practical to carry out this testing (e.g. 
due to the batch size, urgency, etc.), other suitable methods 
should be implemented to ensure that the appropriate quality 
is achieved, in accordance with the risk assessment carried out. 
At a minimum, the starting materials and finished product 
should be examined visually before supply to a patient [40]. 
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Exhibit 6. Reference texts and other sources of information relevant to compounding 
• Martindale: The Complete Drug Reference 
• Trissel’s Stability of Compounded Formulations - Trissel LA 
• International Journal of Pharmaceutical Compounding (www.ijpc.com) 
• Australian Don’t Rush to Crush Handbook - The Society of Hospital Pharmacists of Australia 
• Handbook on Injectable Drugs - American Society of Health - System Pharmacists 
• Pharmaceutical Calculations - Howard C. Ansel and Mitchell J. Stoklosa 
• The Art, Science and Technology of Pharmaceutical Compounding - Loyd Allen 
• Australian Injectable Drugs Handbook - The Society of Hospital Pharmacists of Australia 
• Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems - Loyd Allen 
• Remington: The Science and Practice of Pharmacy, edited by David B. Troy, Paul Beringer 
• Guide to Good Manufacturing Practice for Medicinal Products (can be accessed from the TGA website) 
• Guidelines for the Safe Prescribing, Dispensing and Administration of Cancer Chemotherapy (can be accessed from 
the Clinical Oncological Society of Australia website) 
 
 
Role of the Pharmacists 
Compounding preparations extemporaneously on lawful 
prescription for individual patients is within the pharmacist’s 
purview. Pharmacists and pharmacies are licensed and 
inspected by the states; if a state inspection uncovers 
“manufacturing under the guise of compounding,” it refers the 
matter to the FDA, which can apply cGMP expectations to the 
pharmacist/pharmacy. When a pharmacist engages in large-
scale production of preparations without prescription or 
evidence of pending refills, trending, etc, the practice can be 
regarded as manufacturing; cGMP compliance will be expected, 
including an approved NDA or ANDA. Today, however, 
compounding pharmacies have begun to flourish and are once 
again becoming a vital component of pharmacy practice. Many 
health care professionals recognize that, for some specific 
patient populations, there is a growing need to compound 
certain medications because they are not available through 
conventional manufacturing methods. Whereas the services 
provided by compounding pharmacies give many patients 
options with regard to drug therapy, compounding pharmacists 
must be properly trained to specialize in this aspect of 
pharmacy practice and must have the appropriate resources 
and references to compound quality medications. Pharmacists 
are responsible for ensuring that extemporaneous preparations 
are compounded according to compounding guidelines and 
standards with respect to purity, quality, stability, packing, 
record keeping, and other appropriate pharmacy practices. 
Compounding pharmacists must work closely with the 
prescribing physician to ensure that patient goals are met. A 
positive therapeutic outcome for the patient is the 
fundamental goal for all health care professionals, and, with 
that goal in mind, the services provided by compounding 
pharmacies can continue to make pharmacists an indispensable 
part of the health care team [42,43]. 
 
 
 
 
 
 
 
Conclusion 
Pharmacy compounding provides pharmacists with a unique 
opportunity to practice their time-honored profession. It is 
becoming an even more important part of pharmacy practice in 
the future, including those involved in community and hospital 
care, nursing care, home care, veterinary and other specialty 
practices. It is a practice where the clinical expertise can be 
merged with the scientific expertise of pharmacists to make a 
visible pharmaceutical care. Pharmacists are to be encouraged 
more in compounding but should be aware of the core of 
formulating a specific drug product for a specific patient. This is 
important in providing pharmaceutical care. 
 
Article Summary 
It is important to use a pharmacist’s expertise to adjust dosage 
quantities, frequencies, and even dosage forms for enhanced 
compliance. All pharmacists should understand the options 
presented by compounding. Pharmaceutical compounding is 
increasing for a number of reasons, including the availability of 
a limited number of dosage forms for most drugs, a limited 
number of strengths of most drugs, home health care, hospice, 
the non-availability of drug products/combinations, 
discontinued drugs, drug shortages, orphan drugs, new 
therapeutic approaches and special patient populations. 
Extemporaneously compounded medicines may be useful when 
a required dose or dose form is unavailable commercially, or for 
individualized dosing. There are numerous established 
compounding formulae available, and new formulae may be 
developed with the help of formulation guidelines and 
professional advice. Unlike registered medicines, compounded 
preparations have not generally been assessed for safety and 
efficacy. Their use is off label and is based on extrapolation from 
the component ingredients. Short-term expiry dates are 
provided for compounded products unless their stability has 
been assessed. 
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Abbreviations: Good Compounding Practices (GCPs); Joint 
Commission on Accreditation of Health Care Organizations 
(JCAHO); National Association of Boards of Pharmacy (NABP); 
Control of Substances Hazardous to Health (COSHH); 
Extemporaneous preparations (EPs); National Institute of Child 
Health and Human Development (NICHD); Medicines and 
Healthcare products Regulatory Agency (MHRA); Transmissible 
Spongiform Encephalopathy (TSE); Bovine Spongiform 
Encephalopathy (BSE); Intravenous Fat Emulsion (IVFE); 
American Academy of Pediatrics (AAP); National Association of 
Boards of Pharmacy (NABP); New Drug Application (NDA); 
Abbreviated New Drug Application (ANDA). 
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